DK0779818T3 - Flydende immunglobulinformuleringer - Google Patents

Flydende immunglobulinformuleringer

Info

Publication number
DK0779818T3
DK0779818T3 DK95932006T DK95932006T DK0779818T3 DK 0779818 T3 DK0779818 T3 DK 0779818T3 DK 95932006 T DK95932006 T DK 95932006T DK 95932006 T DK95932006 T DK 95932006T DK 0779818 T3 DK0779818 T3 DK 0779818T3
Authority
DK
Denmark
Prior art keywords
immunoglobulin
immunoglobulin formulations
liquid immunoglobulin
preparations
amphiphilic stabilizers
Prior art date
Application number
DK95932006T
Other languages
English (en)
Inventor
Rene Bruegger
Katharina Gennari
Gerhard Hodler
Bernard Wuest
Original Assignee
Zlb Bioplasma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zlb Bioplasma Ag filed Critical Zlb Bioplasma Ag
Application granted granted Critical
Publication of DK0779818T3 publication Critical patent/DK0779818T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
DK95932006T 1994-09-08 1995-09-07 Flydende immunglobulinformuleringer DK0779818T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9418092A GB9418092D0 (en) 1994-09-08 1994-09-08 Organic compounds
PCT/EP1995/003522 WO1996007429A1 (en) 1994-09-08 1995-09-07 Liquid immunoglobulin formulations

Publications (1)

Publication Number Publication Date
DK0779818T3 true DK0779818T3 (da) 2003-11-24

Family

ID=10761028

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95932006T DK0779818T3 (da) 1994-09-08 1995-09-07 Flydende immunglobulinformuleringer

Country Status (27)

Country Link
US (1) US5871736A (da)
EP (1) EP0779818B1 (da)
JP (1) JP3004729B2 (da)
KR (1) KR100370631B1 (da)
CN (1) CN1157572A (da)
AT (1) ATE246005T1 (da)
AU (1) AU700788B2 (da)
BR (1) BR9508821A (da)
CA (1) CA2197432C (da)
CZ (1) CZ285967B6 (da)
DE (1) DE69531400T2 (da)
DK (1) DK0779818T3 (da)
FI (1) FI970603A0 (da)
GB (1) GB9418092D0 (da)
HU (1) HU223668B1 (da)
IL (1) IL115226A (da)
MX (1) MX9701510A (da)
NO (1) NO971016L (da)
NZ (1) NZ292919A (da)
PL (1) PL182738B1 (da)
PT (1) PT779818E (da)
RO (1) RO118568B1 (da)
RU (1) RU2158605C2 (da)
SK (1) SK282332B6 (da)
TW (1) TW407056B (da)
WO (1) WO1996007429A1 (da)
ZA (1) ZA957583B (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0827751T3 (da) * 1996-09-06 2003-03-31 Chemo Sero Therapeut Res Inst Medicinsk præparat indeholdende vævsplasminogenaktivator og nicotinamid
GB9705810D0 (en) * 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
ES2568899T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
ES2332402T5 (es) * 2000-10-12 2018-05-14 Genentech, Inc. Formulaciones de proteína concentradas de viscosidad reducida
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
SI2335725T1 (sl) 2003-04-04 2017-01-31 Genentech, Inc. Visokokoncentrirane formulacije protiteles in proteinov
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
ES2562912T5 (es) 2003-10-01 2020-02-18 Kyowa Hakko Kirin Co Ltd Procedimiento de estabilización de un anticuerpo y preparación de anticuerpo de tipo disolución estabilizada
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
AU2014201388C1 (en) * 2006-12-21 2017-02-02 Amgen Inc. Stable Buffered Formulations Containing Polypeptides
WO2008079290A2 (en) * 2006-12-21 2008-07-03 Amgen Inc Stable buffered formulations containing polypeptides
WO2009002521A2 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
KR101087017B1 (ko) 2007-07-10 2011-12-09 (주)메디톡스 보툴리눔 독소의 안정성이 개선된 약제학적 액상 조성물
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
SG174258A1 (en) * 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
CN102459331B (zh) 2009-05-27 2015-01-28 巴克斯特国际公司 生产用于皮下使用的高度浓缩的免疫球蛋白制品的方法
MX2012003282A (es) 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
DK2531218T3 (da) 2010-02-04 2019-04-01 Csl Behring Ag Immunoglobulinpræparat
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
MX2012010198A (es) 2010-03-01 2012-10-03 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi).
FR2961107B1 (fr) 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
AU2011301803A1 (en) 2010-09-17 2013-03-21 Baxalta GmbH Stabilization of immunoglobulins and other proteins through aqueous formulations with sodium chloride at weak acidic to neutral pH
US20150157619A1 (en) * 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
RU2675824C2 (ru) 2013-09-11 2018-12-25 Игл Байолоджикс, Инк. Жидкие белковые составы, содержащие ионные жидкости
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
SG11201702614SA (en) 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US20240052020A1 (en) * 2020-09-27 2024-02-15 Emergent Biosolutions Canada Inc. Hyperimmune globulin formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362661A (en) * 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
CA1153695A (en) * 1979-08-30 1983-09-13 Syoji Ono S-sulfonated immunoglobulin composition having a high monomer content and a process for production thereof
JPS56135418A (en) * 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
JPS60120823A (ja) * 1983-12-02 1985-06-28 Green Cross Corp:The IgG単量体
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
JPH0825903B2 (ja) * 1985-05-16 1996-03-13 株式会社ミドリ十字 γ―グロブリン含有水溶液
JPH02290822A (ja) * 1989-04-04 1990-11-30 Eli Lilly & Co 医薬製剤
JP2942412B2 (ja) * 1991-12-26 1999-08-30 鐘紡株式会社 化粧料

Also Published As

Publication number Publication date
CZ285967B6 (cs) 1999-12-15
CN1157572A (zh) 1997-08-20
CA2197432C (en) 2008-11-04
PT779818E (pt) 2003-11-28
FI970603A (fi) 1997-02-12
AU700788B2 (en) 1999-01-14
SK30097A3 (en) 1997-10-08
ATE246005T1 (de) 2003-08-15
EP0779818B1 (en) 2003-07-30
HU223668B1 (hu) 2004-11-29
IL115226A (en) 1999-08-17
KR100370631B1 (ko) 2003-04-18
US5871736A (en) 1999-02-16
DE69531400T2 (de) 2004-05-27
RO118568B1 (ro) 2003-07-30
FI970603A0 (fi) 1997-02-12
CZ68497A3 (en) 1997-06-11
PL318265A1 (en) 1997-05-26
EP0779818A1 (en) 1997-06-25
RU2158605C2 (ru) 2000-11-10
SK282332B6 (sk) 2002-01-07
MX9701510A (es) 1997-05-31
TW407056B (en) 2000-10-01
NZ292919A (en) 1998-12-23
WO1996007429A1 (en) 1996-03-14
PL182738B1 (pl) 2002-02-28
HUT77122A (hu) 1998-03-02
BR9508821A (pt) 1997-12-23
GB9418092D0 (en) 1994-10-26
ZA957583B (en) 1997-03-10
NO971016D0 (no) 1997-03-05
IL115226A0 (en) 1995-12-31
CA2197432A1 (en) 1996-03-14
AU3522995A (en) 1996-03-27
NO971016L (no) 1997-03-05
DE69531400D1 (de) 2003-09-04
JP3004729B2 (ja) 2000-01-31
JPH10502938A (ja) 1998-03-17

Similar Documents

Publication Publication Date Title
DK0779818T3 (da) Flydende immunglobulinformuleringer
FI101303B (fi) Menetelmä terapeuttisesti käyttökelpoisten 7-(2-tio-2-okso)metyyliamin o-5-okso-pyrrolo- ja -6-okso-pyrido- ja -pyratsino£2,1-a|£2|bentsatsep iini- ja -oksatsino- ja -tiatsino£3,4-a|£2|bentsatsepiini-4-karboksyyl ihappojohdannaisten valmistamiseksi
NO305244B1 (no) Heterocykliske derivater som inhibitorer for blodplateaggregering, anvendelse derav og farmas°ytisk blanding
DE69610627D1 (de) Neuartige peptidderivate
ES2032382T3 (es) Metodo para preparar un medicamento para la prevencion o tratamiento de la endometriosis.
HUT65278A (en) Process for producing pyrido-, pyrrolo-, thiazino-, oxazino- and pyrazino-benzazepine derivatives and pharmaceutical preparations containing them
NO941937D0 (no) Sakarinderivater som inhiberer proteolytiske enzymer
DE69709407T2 (de) Zytotoxischer aminozucker und verwandte zuckerderivate von indolopyrrolocarbazolen
DE69818286D1 (de) Pyridylverbindungen und diese enthaltende pharmazeutische zubereitungen
ATE130315T1 (de) Hirudin-derivate mit verzögerter wirkung.
DE69808475T2 (de) Aminosäurederivate zur behandlung von schlaganfall
NO178540C (no) Bisfenyletanderivater, farmasöytisk preparat derav samt anvendelse
DK573886A (da) Fremgangsmaade til fremstilling af beskyttede argininholdige peptider
FR2714291B1 (fr) Application des dérivés de la pyridone à titre de médicaments anesthésiques.
NO970350D0 (no) Forbindelser anvendelige som anti-formeringsmidler og GARFT-inhibitorer
HUT65256A (en) Process for producing 2-mercapto methylene-tetrahydronaphtalene-2-carboxamide derivatives and pharmaceutical preparations containing them
DE3863499D1 (de) Schaedlingsbekaempfungsmittel auf basis von derivaten des 2,3-diaminomaleinsaeurenitrils.